Boehringer sinks €100M into Respimat production; Impax inks shareholder lawsuit settlement;

@FiercePharma: ICYMI: This week's issue of FierceAnimalHealth. Subscribe here to get it every week. | Follow @FiercePharma

@TracyStaton: ICYMI yesterday: Bristol-Myers' oncology star lines up for lung cancer approval, leading the PD-1 pack. Story from FierceBiotech | Follow @TracyStaton

@CarlyHFierce: Once-rejected drugs in Gilead's Stribild get FDA nod to go it alone. Story | Follow @CarlyHFierce

> Boehringer Ingelheim is beefing up its Dortmund, Germany, plant to turn out more Respimat inhalers, with a €100 million investment ($126 million) and 100 new jobs. Report

> Generics maker Impax Laboratories ($IPXL) said it will pay $8 million to settle a shareholder lawsuit over allegations that it didn't tell the full truth about FDA inspections at a troubled California plant. Report

> Baxter ($BAX) plans a new R&D facility in Cambridge, MA, for the pharma business it plans to spin off next year under the name Baxalta. Report

> A U.S. judge says securities regulators can go after two Dubai residents for allegedly engaging in insider trading around Amgen's ($AMGN) 2013 deal to buy Onyx Pharmaceuticals. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Activist investor intensifies pressure on Volcano. Article | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study nanomed delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@VarunSaxena2: Interesting tidbit about off-label use: biliary stents have been used for cardiac indications in the past, panelists say. | Follow @VarunSaxena2

@EmilyWFierce: Closed-loop epidural stimulation system helped paralyzed rats take 1,000 steps and navigate "rodent-sized stairs." More from MIT Technology Review | Follow @EmilyWFierce

> Study: Publicly available information about 510(k) devices' safety and effectiveness lacking. Article

> Israeli devicemaker eyes lucrative sleep disorder market. Story

> Microsoft, Aerocrine partner to send asthma device data to the cloud. Report

Biotech News

@FierceBiotech: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here | Follow @FierceBiotech

@JohnCFierce: Baxter inks a big lease in the heart of Cambridge for biopharma R&D headquarters - (more for hubs, less for Chicago). Article | Follow @JohnCFierce

@DamianFierce: buying antiviral outfit Alios for $1.75B in cash(!). Press release | Follow @DamianFierce

@EmilyMFierce: New class of antibiotics could fight drug-resistant tuberculosis. FierceBiotech Research story | Follow @EmilyMFierce

> Takeda steps up with $1.6B package of milestones in MacroGenics R&D pact. More

> Regeneron's would-be blockbuster completes the allergic circle with Phase II success. Article

> J&J makes a splash in hep C with a $1.75B deal for Alios. News

Biotech Research News

> New class of antibiotics could fight drug-resistant tuberculosis. More

> Protein 'map' points way to combating chemo-resistant cancer. Report

> Scientists replicate ALS dementia in mice. Item

> Hemispherx to test FDA-rejected drug, other candidates against Ebola. Article

> Monkey study reveals clues for HIV eradication. Story

Pharma Manufacturing News

> Report: Indian government to take legal action over drug quality paper. Item

> Apotex tries to 'set the record straight' after Health Canada quarantine request. More

> FDA warns of contaminated Chinese meds after toddler suffers lead poisoning. Article

> Strides and Shasun plan merger to create big, 'de-risking' production network. Story

> Credit Suisse: FDA 483 unlikely to lead to import alert for Sun. Report

And Finally... Working long hours may be boosting the risk of Type 2 diabetes. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.